Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €149.26 EUR
Change Today -2.46 / -1.62%
Volume 0.0
J7Z On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 2:28 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

jazz pharmaceuticals plc (J7Z) Snapshot

Open
€150.72
Previous Close
€151.73
Day High
€151.84
Day Low
€149.22
52 Week High
07/31/15 - €177.72
52 Week Low
10/15/14 - €108.11
Market Cap
9.2B
Average Volume 10 Days
56.4
EPS TTM
--
Shares Outstanding
61.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for JAZZ PHARMACEUTICALS PLC (J7Z)

jazz pharmaceuticals plc (J7Z) Related Businessweek News

No Related Businessweek News Found

jazz pharmaceuticals plc (J7Z) Details

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate that is in phase I clinical trail for use in patients with narcolepsy. In addition, it develops products in the areas of hematology and oncology, such as JZP-416, which has completed phase I clinical trial for the treatment of patients with ALL who are hypersensitive to E. coli-derived asparaginase; and Leukotac, an anti-CD25 monoclonal antibody that is in phase III clinical trials for the treatment of steroid-refractory acute graft vs. host disease. The company is headquartered in Dublin, Ireland.

855 Employees
Last Reported Date: 08/5/15

jazz pharmaceuticals plc (J7Z) Top Compensated Officers

Co-Founder, Executive Chairman and Chief Exec...
Total Annual Compensation: $830.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $402.9K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $493.5K
Executive Vice President and General Counsel
Total Annual Compensation: $483.5K
Senior Vice President of U.S. Commercial
Total Annual Compensation: $296.2K
Compensation as of Fiscal Year 2014.

jazz pharmaceuticals plc (J7Z) Key Developments

Jazz Pharmaceuticals Public Limited Company Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Full Year of 2015

Jazz Pharmaceuticals Public Limited Company announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $333,747,000 compared to $291,230,000 a year ago. Income from operations was $153,301,000 compared to $74,291,000 a year ago. Income before income tax provision was $118,760,000 compared to $62,936,000 a year ago. Net income attributable to the company was $88,114,000 or $1.40 per diluted ordinary share compared to $43,659,000 or $0.70 per diluted ordinary share a year ago. Non-GAAP adjusted net income attributable to the company was $152,179,000 or $2.41 per diluted share compared to $125,930,000 or $2.02 per diluted share a year ago. Adjusted income before income tax provision was $188,575,000 compared to $156,351,000 a year ago. For the six months, the company reported total revenues of $643,050,000 compared to $538,149,000 a year ago. Income from operations was $270,060,000 compared to $7,632,000 a year ago. Income before income tax provision was $221,519,000 compared to loss before income tax provision of $13,676,000 a year ago. Net income attributable to the company was $158,814,000 or $2.52 per diluted ordinary share compared to net loss attributable to the company of $48,991,000 or $0.83 per diluted ordinary share a year ago. Non-GAAP adjusted net income attributable to the company was $277,247,000 or $4.40 per diluted share compared to $225,468,000 or $3.61 per diluted share a year ago. Adjusted income before income tax provision was $343,554,000 compared to $279,129,000 a year ago. For the full year of 2015, the company expects GAAP net income attributable to the company in the range of $323 million to $356 million, intangible asset amortization in the range of $94 million to $104 million, noncash interest expense in the range of $23 million to $27 million, non-GAAP adjusted net income attributable to the company of $595 million to $614 million, GAAP net income attributable to the company per diluted share in the range of $5.17 to $5.70 and non-GAAP adjusted net income attributable to the company per diluted share in the range of $9.45 to $9.75. The company expects revenues in the range of $1,310 million to $1,370 million, total net profit sales in the range of $1,303 million to $1,363 million, adjusted gross margin in the range of 92% to 93%, adjusted interest expense of $40 million.

Jazz Pharmaceuticals Public Limited Company to Report Q2, 2015 Results on Aug 05, 2015

Jazz Pharmaceuticals Public Limited Company announced that they will report Q2, 2015 results at 4:30 PM, Eastern Daylight on Aug 05, 2015

Jazz Pharmaceuticals Public Limited Company, Q2 2015 Earnings Call, Aug 05, 2015

Jazz Pharmaceuticals Public Limited Company, Q2 2015 Earnings Call, Aug 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
J7Z:GR €149.26 EUR -2.46

J7Z Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $39.79 USD -1.24
Alkermes PLC $59.56 USD -3.59
BioMarin Pharmaceutical Inc $129.24 USD -3.94
Impax Laboratories Inc $40.96 USD -1.44
Incyte Corp $116.19 USD -3.74
View Industry Companies
 

Industry Analysis

J7Z

Industry Average

Valuation J7Z Industry Range
Price/Earnings 42.0x
Price/Sales 8.3x
Price/Book 7.3x
Price/Cash Flow 28.1x
TEV/Sales 6.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JAZZ PHARMACEUTICALS PLC, please visit www.jazzpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.